Quantcast

Latest TH-302 Stories

2011-05-11 12:34:00

Investigational cancer drug targets oxygen supply in tumors, advances for additional testing SCOTTSDALE, Ariz., May 11, 2011 /PRNewswire-USNewswire/ -- An investigational drug shows promise targeting oxygen supply in tumors, according to results of a study completed at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and published in the current issue of Clinical Cancer Research. (Photo: http://photos.prnewswire.com/prnh/20110511/DC00318 ) Significant responses were...

2008-10-23 12:00:06

Threshold Pharmaceuticals, a biotechnology company, has announced encouraging preliminary results from the Phase I study of its clinical stage hypoxia-activated prodrug, TH-302. Preliminary results from 22 patients were reported in an ongoing Phase I clinical trial evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors. Preliminary efficacy signals have been observed in two patients enrolled in the ongoing Phase I trial. As previously reported,...

2008-09-16 09:00:15

REDWOOD CITY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. "The treatment of soft tissue sarcomas continues to be a difficult challenge. New therapeutic and novel agents are required to improve the...

2008-08-12 09:00:38

REDWOOD CITY, Calif., Aug. 12, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a clinical trial of TH-302 in combination with various chemotherapeutic agents in patients with advanced solid tumors. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. "Targeting tumor hypoxia is an exciting area of cancer research, and may offer great promise to patients with a wide variety of cancers,"...

2008-07-25 12:01:21

Cornerstone Pharmaceuticals has received clearance from the FDA to begin a Phase I/II clinical trial evaluating the safety and early efficacy of its first-in-class altered energy metabolism-directed compound, CPI-613, in a variety of cancer types. The approved clinical trial will be open to patients with a variety of tumor types who have failed previous therapies. It will be conducted at a limited number of clinical trial sites in North America. The CPI-613 trial is designed as an open...

2008-07-24 09:01:14

REDWOOD CITY, Calif., July 24, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that Herbert Hurwitz, M.D. has joined the Company's Scientific Advisory Board (SAB). Dr. Hurwitz is an Associate Professor of Medicine at Duke University Medical Center and a medical oncologist at the Duke Comprehensive Cancer Center. "Tumor hypoxia is a promising area that is gaining a great deal of attention among the medical research community," said Herbert Hurwitz, M.D....

2008-07-23 09:01:21

Threshold Pharmaceuticals has announced positive results from an ongoing Phase I clinical trial evaluating the safety and preliminary efficacy of TH-302 in patients with advanced solid tumors. The clinical trial was designed with an initial accelerated titration design followed by a standard dose escalation schema. The trial has completed the accelerated titration design component and has enrolled the eighth dosing cohort. The weekly dose has been escalated from the initial dose of...

2008-07-22 09:00:21

REDWOOD CITY, Calif., July 22, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine: Cancer Clinical Trials and Personalized Medicine, being held July 20-23, 2008, at the Hyatt Regency Hotel in Monterey, CA. Translational research with the incorporation of laboratory scientific...

2008-07-08 09:00:12

ImmunoGen has started patient dosing in a Phase I clinical trial evaluating the company's IMGN388 targeted anticancer compound for the treatment of solid tumors. The Phase I trial (Study 201) underway at South Texas Accelerated Research Therapeutics in San Antonio, Texas is designed to assess the tolerability and pharmacokinetics of IMGN388 in patients with solid tumors; efficacy information also will be obtained. Increasing doses of the compound, administered every three weeks, are to...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related